TrialJournal of diabetes science and technology2014

Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulin.

Laura E Trask et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.